The data suggest that six cycles of TC represent an effective chemotherapy option with less toxicity for HER2-negative early breast cancer and based on these results the indication for TC6 could be expanded towards intermediate-risk early breast cancer patients. Here, ERBB2 is linked to breast carcinoma.